CECR2

Across TCGA pan-cancer cohorts, CECR2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of CECR2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where CECR2 RNA is repressed in tumor relative to normal tissue. In most cancer types CECR2 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, KICH, and KIRC are the cancer types where CECR2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CECR2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	−1.562	<.001	11	view →
KICH	Male	III,IV	−0.860	<.001	9	view →
KIRC	Male	All	−0.661	<.001	9	view →
CHOL	All	All	−1.307	<.001	5	view →
LUAD	All	All	−0.582	<.001	5	view →
HNSC	Female	All	+0.788	.007	4	view →
UCEC	All	All	−0.707	.001	4	view →
BRCA	Female	II,III,IV	+0.381	.005	4	view →
LIHC	Male	All	+0.694	<.001	3	view →
COAD	All	All	+0.218	.008	3	view →
PRAD	All	All	+0.993	<.001	2	view →
PAAD	All	All	−0.287	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

CECR2–THCA

Open the THCA breakdown →